Receptor antagonism/agonism can be uncoupled from pharmacoperone activity

Area of Science:

• Pharmacology
• Molecular Biology
• Genetics

Background:

• Mutations in the vasopressin receptor type 2 (V2R) cause nephrogenic diabetes insipidus, often due to misrouting of the receptor.
• Pharmacoperones are compounds designed to correct these trafficking defects.
• Previous high-throughput screening identified potential pharmacoperones for V2R mutants.

Purpose of the Study:

• To evaluate previously identified V2R pharmacoperone candidates using an orthologous assay.
• To investigate the relationship between pharmacoperone activity and receptor antagonism/agonism.
• To identify novel pharmacoperones with improved therapeutic potential.

Main Methods:

• Utilized an orthologous assay to screen a library of V2R pharmacoperone candidates.
• Assessed the antagonistic and agonistic activities of identified active pharmacoperones.
• Compared the pharmacological profiles of newly identified pharmacoperones with existing ones.

Main Results:

• No consistent correlation was found between V2R pharmacoperone activity and receptor antagonism or agonism.
• Active pharmacoperones were identified that exhibited minimal antagonistic effects.
• This finding contrasts with previous studies where pharmacoperones were primarily selected from peptidomimetic antagonists.

Conclusions:

• Novel V2R pharmacoperones with minimal antagonistic activity have been identified.
• These compounds demonstrate a broader therapeutic potential for nephrogenic diabetes insipidus.
• The findings suggest that pharmacoperones do not require significant antagonistic properties for efficacy, potentially simplifying their clinical application.